Tinlarebant
Tinlarebant is a investigational new drug that is being evaluated to treat dry macular degeneration and Stargardt disease.
Snapshot
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Tinlarebant is a investigational new drug that is being evaluated to treat dry macular degeneration and Stargardt disease. It is a retinol binding protein 4 antagonist.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370543364 under CC BY-SA 4.0; modifications have been made.